Abstract: The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4.sup.+ T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4.sup.+ T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C-C' loop of the D1 domain; residues 317-323, the C-C' loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.

Abstract: This invention relates to a novel protein capable of inducing an immune response protective against human malarial infection caused by Plasmodium falciparum, and to the cloning and expression of a gene encoding the said protein. The invention further relates to novel vaccines comprising the said protein and to their use in the vaccination of humans at risk from malaria.

Abstract: The invention relates to a composition comprising among others a fibrinopeptide A releasing compound. Furthermore the invention relates to the use of the composition as calibrator in plasma containing fibrinogen. A test kit comprising the said composition and a method to determine soluble fibrin also belong to the invention.

Abstract: The present invention provides an improved method and apparatus for growing biomass particles, particularly microcarrier-bound cells, in an agitated suspension culture vessel in which fresh culture medium is added and spent culture medium is withdrawn continuously or semi-continuously. The improvement comprises withdrawing the spent culture medium through a particle settling chamber located within the vessel and at least partially immersed in the agitated culture medium therewithin. The particle settling chamber comprises a hollow container with a bottom opening through which biomass particles, such as microcarrier-bound cells, settle by gravity back into the agitated culture medium and a top opening through which particle-free spent culture medium is withdrawn form the vessel. The settling chamber is configured such that the fluid velocity of culture medium entering the settling chamber through the bottom opening is significantly less than the biomass particle settling velocity.